FDA clears new version of Hologic's Mammosite
This article was originally published in Clinica
The US FDA has granted 510(k) clearance for Hologic's MammoSite ML radiation therapy system, a targeted breast cancer treatment. The device is a new version of the company's single-lumen MammoSite system, which was first cleared in the US in 2002. MammoSite ML has a multi-lumen design, which allows oncologists to better target the radiation dose. This enables treatment of patients who would otherwise not be candidates for traditional brachytherapy, such as those with tumours close to the skin or chest wall, Bedford, Massachusetts-based Hologic said. Both systems are comprised of an inflatable balloon catheter which is inserted into the cavity created by a lumpectomy, and through which radiation is delivered.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.